ReNeuron Group Past Earnings Performance
Past criteria checks 0/6
ReNeuron Group has been growing earnings at an average annual rate of 17.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 51.6% per year.
Key information
17.8%
Earnings growth rate
30.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -51.6% |
| Return on equity | -209.5% |
| Net Margin | -2,037.3% |
| Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ReNeuron Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -5 | 3 | 0 |
| 30 Jun 23 | 0 | -5 | 3 | 0 |
| 31 Mar 23 | 1 | -5 | 3 | 0 |
| 31 Dec 22 | 1 | -7 | 3 | 0 |
| 30 Sep 22 | 1 | -8 | 4 | 0 |
| 30 Jun 22 | 1 | -9 | 4 | 0 |
| 31 Mar 22 | 0 | -10 | 4 | 0 |
| 31 Dec 21 | 0 | -10 | 4 | 0 |
| 30 Sep 21 | 0 | -9 | 4 | 0 |
| 30 Jun 21 | 0 | -10 | 4 | 0 |
| 31 Mar 21 | 0 | -11 | 4 | 0 |
| 31 Dec 20 | 0 | -13 | 4 | 0 |
| 30 Sep 20 | 0 | -15 | 4 | 0 |
| 30 Jun 20 | 3 | -13 | 4 | 0 |
| 31 Mar 20 | 6 | -11 | 4 | 0 |
| 31 Dec 19 | 6 | -12 | 5 | 0 |
| 30 Sep 19 | 6 | -13 | 5 | 0 |
| 30 Jun 19 | 5 | -14 | 5 | 0 |
| 31 Mar 19 | 3 | -14 | 5 | 0 |
| 31 Dec 18 | 3 | -14 | 5 | 0 |
| 30 Sep 18 | 3 | -13 | 5 | 0 |
| 30 Jun 18 | 2 | -16 | 5 | 0 |
| 31 Mar 18 | 1 | -18 | 5 | 0 |
| 31 Dec 17 | 1 | -18 | 4 | 0 |
| 30 Sep 17 | 1 | -17 | 4 | 0 |
| 30 Jun 17 | 1 | -17 | 4 | 0 |
| 31 Mar 17 | 1 | -16 | 4 | 0 |
| 31 Dec 16 | 1 | -15 | 4 | 0 |
| 30 Sep 16 | 1 | -15 | 4 | 0 |
| 30 Jun 16 | 1 | -13 | 4 | 0 |
| 31 Mar 16 | 1 | -11 | 4 | 0 |
| 31 Dec 15 | 1 | -10 | 4 | 0 |
| 30 Sep 15 | 1 | -9 | 4 | 0 |
| 30 Jun 15 | 1 | -9 | 4 | 0 |
| 31 Mar 15 | 1 | -9 | 4 | 0 |
| 31 Dec 14 | 1 | -8 | 3 | 0 |
| 30 Sep 14 | 1 | -8 | 3 | 0 |
| 30 Jun 14 | 1 | -8 | 3 | 0 |
| 31 Mar 14 | 1 | -7 | 3 | 0 |
| 31 Dec 13 | 0 | -7 | 2 | -1 |
| 30 Sep 13 | 0 | -7 | 2 | -2 |
| 30 Jun 13 | 0 | -6 | 2 | -1 |
Quality Earnings: RNUG.F is currently unprofitable.
Growing Profit Margin: RNUG.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RNUG.F is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare RNUG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNUG.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: RNUG.F has a negative Return on Equity (-209.54%), as it is currently unprofitable.